SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong

ABSTRACT The SARS-CoV-2 Omicron variant has led to a major wave of COVID-19 in Hong Kong between January and May 2022. Here, we used seroprevalence to estimate the combined incidence of vaccination and SARS-CoV-2 infection, including subclinical infection which were not diagnosed at the acute stage. The overall seropositive rate of IgG against receptor binding domain (anti-RBD IgG) increased from 52.2% in December 2021 to 89.3% in May 2022. The level of anti-RBD IgG was lowest in the 0–9 and ≥80 year-old age groups in May 2022. The seropositive rate of antibody against ORF8, which reflects the rate of prior infection, was 23.4% in May 2022. Our data suggest that although most individuals were either vaccinated or infected after the fifth wave, children and older adults remain most vulnerable. Public health measures should target these age groups in order to ameliorate the healthcare consequences of upcoming waves.

[1]  K. To,et al.  Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong , 2022, Nature Communications.

[2]  M. Ajelli,et al.  Modeling transmission of SARS-CoV-2 Omicron in China , 2022, Nature Medicine.

[3]  N. Garrett,et al.  Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa , 2022, The New England journal of medicine.

[4]  R. Iachan,et al.  Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[5]  O. Tsang,et al.  Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines , 2022, eBioMedicine.

[6]  K. To,et al.  Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source community outbreak , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Madhi,et al.  South African Population Immunity and Severe Covid-19 with Omicron Variant , 2022, The New England journal of medicine.

[8]  Gheyath K Nasrallah,et al.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.

[9]  K. To,et al.  Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine , 2022, Emerging microbes & infections.

[10]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[11]  O. Tsang,et al.  Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.

[12]  K. To,et al.  Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19 , 2021, The Lancet Regional Health - Western Pacific.

[13]  Denis Sauré,et al.  Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study , 2021, The Lancet Infectious Diseases.

[14]  K. To,et al.  Nosocomial outbreak of COVID-19 by possible airborne transmission leading to a superspreading event , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  K. To,et al.  Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein , 2020, mBio.